HCW Biologics Inc. recently announced Peter Rhode, PhD, Chief Scientific Officer and Vice President of Clinical Operations of HCW Biologics, participated in a Virtual Investor “What This Means” segment.

As part of the segment, Dr. Rhode discussed the Company’s recent news announcing its TRBC-based second-generation T-Cell Engager (“TCE”) program and the positive safety profile from a non-human primate investigative study recently conducted by the Company for its TCE program. HCW Biologics believes its second-generation TCEs could alleviate the challenges of the first generation TCEs, such as complex manufacturing processes, tolerability, safety, antigen selection, and efficacy for solid tumors. The Company has joined a small group of innovative biotechnology companies who have discovered new TCEs that overcome resistance mechanisms and improve the ability to treat solid tumors.

The Virtual Investor “What This Means” segment featuring HCW Biologics is now available here.

HCW Biologics Inc. (NASDAQ: HCWB) is a clinical-stage biopharmaceutical company developing proprietary immunotherapies to treat diseases promoted by chronic inflammation, especially age-related and senescence-associated diseases. The Company’s immunotherapeutics represent a new class of drugs that it believes have the potential to fundamentally change the treatment of cancer and many other diseases and conditions that are promoted by chronic inflammation — and in doing so, improve patients’ quality of life and potentially extend longevity. Chronic inflammation, including inflammaging, is believed to be a significant contributing factor to senescence-associated diseases and conditions that diminish healthspan, including many types of cancer, autoimmune diseases, and neurodegenerative diseases, as well as many indications that impact quality-of-life that are not life-threatening. The Company’s lead product candidate, HCW9302, was developed using the Company’s legacy TOBI™ (Tissue factOr-Based fusIon) platform. The Company has created another drug discovery technology, the TRBC platform, which is not based on Tissue Factor. The TRBC platform has the capability to construct immunotherapeutics that not only activate and target immune responses but are also equipped with receptors that specifically target cancerous or infected cells. This platform is a versatile scaffold that enables the creation of multiple classes of immunotherapeutic compounds: Class I: Multi-Functional Immune Cell Stimulators; Class II: Second-Generation Immune Checkpoint Inhibitors; Class III: Multi-Specific Targeting Fusions and Enhanced Immune Cell Engagers. These novel immunotherapeutics are being developed for treatment of a wide range of disease indications, including oncology, autoimmune diseases, and improving quality of life conditions. The Company has constructed over 50 molecules using the TRBC platform. Further preclinical evaluation studies are currently being conducted for these molecules the Company has selected based on promising preclinical data. The Company has two licensing programs in which it has licensed exclusive rights for some of its proprietary molecules. See the Company Pipeline at https://hcwbiologics.com/pipeline/